|

68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients

RECRUITINGN/ASponsored by Peking Union Medical College Hospital
Actively Recruiting
PhaseN/A
SponsorPeking Union Medical College Hospital
Started2022-04-15
Est. completion2025-01-01
Eligibility
Age18 Years – 90 Years
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05324332

Summary

Prostate-specific membrane antigen (PSMA)-targeted PET imaging with 68Ga-labeled compounds is able to provide superior sensitivity and specificity to detect primary prostate tumor and its metastases, like the most widely studied 68Ga-PSMA-11. This pilot study was evaluate the diagnostic performance of 68Ga-P16-093, a novel radiopharmaceutical targeting PSMA, which was compared with 68Ga-PSMA-11 in the same group of primary prostate cancer patients.

Eligibility

Age: 18 Years – 90 YearsSex: MALEHealthy volunteers accepted
Inclusion Criteria:

* histologically confirmed untreated primary prostate cancer patients;
* 68Ga-PSMA-11 and 68Ga-P16-093 PET/CT within a week;
* signed written consent.

Exclusion Criteria:

* known allergy against PSMA;
* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Conditions2

CancerProstate Cancer

Interventions2

68Ga-P16-09368Ga-PSMA-11

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.